Thalia Therapeutics

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Media

AIM Rule 26

Regulatory news

Home

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

New-generation silica nanoparticles: the next big thing in siRNA delivery systems for cancer treatment?

In our latest article, we look at how Nuvec® offers an alternative to current drug delivery approaches for small interfering RNA (siRNA). Not only is Nuvec® particularly suited to chemical modification, allowing the addition of target specific ligands to receptors on cancer cells, but it may offer the convenience of oral rather than parenteral delivery. Using targeted systems to deliver oligonucleotides, Nuvec® shows great promise as a tactic for the treatment of many diseases, including cancer. By using a more targeted approach, the drawbacks of conventional chemotherapy treatment, such as undesirable side effects, can be avoided.

Read the article published in Manufacturing Chemist below.

Article: Could new-generation silica nanoparticles be the next big thing in siRNA delivery systems for cancer treatment?

Article: Could new-generation silica nanoparticles be the next big thing in siRNA delivery systems for cancer treatment? 